Cytosorbents Q2 2026 Earnings Call: Nears Cash Flow Breakeven, Advances FDA Path for DrugSorb-ATR
CTSO is trading near its 52-week low of $0.35 (7.0% above the low).
Summary
Cytosorbents' Q2 2026 earnings call presentation shows the company nearing operating cash flow breakeven while advancing a new FDA submission plan for its lead product candidate, DrugSorb-ATR, against a backdrop of a going concern warning and an upcoming reverse stock split vote.
Key Events · Earnings and Guidance · CTSO
-
Q2 2026 Financial Results
Revenue flat at $9.6 million; net loss widened to $4.4 million ($0.07/share) driven by non-cash charges, but operating cash burn fell to ~$0.4 million, down from $6-7 million quarterly run rates in 2023.
-
Cash Flow Breakeven Target
Management reiterated expectations to reach operating cash flow breakeven in 2H 2026, supported by a 23% headcount reduction since September 2025 and improved gross margins to 73%.
-
DrugSorb-ATR FDA Path
Following FDA denial of the initial De Novo application, the company plans a new submission for ticagrelor removal based on additional mechanistic data and real-world evidence, with a pre-submission meeting scheduled later in August 2026. A parallel De Novo submission for DOAC removal is also being explored.
-
Reverse Stock Split Vote
A shareholder vote on a reverse stock split is set for August 13, 2026, aimed at regaining Nasdaq compliance; the stock closed at $0.3744 on August 7, 2026.
Analysis · CTSO · Industrial Applications And Services
Cytosorbents furnished its Q2 2026 earnings presentation, revealing a net loss of $4.4 million on flat revenue of $9.6 million, but with a sharply reduced operating cash burn of just $0.4 million. The company reiterated its goal of reaching operating cash flow breakeven in the second half of 2026, a critical milestone given its going concern warning and only $5.9 million in cash. The presentation also detailed a new FDA regulatory strategy for its DrugSorb-ATR device, including a planned De Novo submission for ticagrelor removal and a parallel path for DOAC removal, following the prior denial. With a reverse stock split vote scheduled for August 13, 2026, to address Nasdaq delisting risk, the filing underscores both the progress toward financial stability and the high-stakes regulatory catalysts ahead.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 32.3% of the 2077 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTSO was trading at $0.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $22.6M. The 52-week trading range was $0.35 to $1.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.